RNA療法市場：技術、適応症、エンドユーザー別-2025-2030年の世界予測

RNA療法市場は、2023年に21億8,000万米ドルと評価され、2024年には26億米ドルに達すると予測され、CAGR 22.38％で成長し、2030年には89億8,000万米ドルに達すると予測されています。

RNA療法は、バイオテクノロジーおよび製薬業界の最先端セグメントであり、さまざまな疾患の治療にRNA分子を使用することに焦点を当てています。この革新的なアプローチには、RNA干渉（RNAi）、アンチセンス・オリゴヌクレオチド（ASO）、メッセンジャーRNA（mRNA）療法が含まれ、これらは遺伝物質を標的とし、操作することによって作用します。RNA治療の必要性は、従来の低分子やタンパク質ベースの治療法では対処が困難な病態を治療できる可能性があることに起因しており、正確な遺伝子修正が重要な遺伝性疾患、がん、希少疾患への応用が期待されています。RNA療法の最終用途と応用範囲は拡大しており、創薬、臨床試験、個別化医療に多額の投資が行われています。主な成長要因としては、送達技術の進歩、RNAメカニズムの理解の深まり、有利な規制の枠組みなどが挙げられます。RNA療法市場のイノベーションにおける最新の潜在的機会は、デリバリーシステムの改良、治療ターゲットの拡大、費用対効果の高い製造プロセスの開発にあります。学術機関やバイオテクノロジー企業との提携や協力に焦点を当てることで、イノベーションはさらに加速される可能性があります。しかし、デリバリーの有効性、免疫原性の問題、開発コストの高さといった課題は、規制上のハードルや市場競争と並んで大きな制約となっています。技術革新の機が熟している分野には、ナノ粒子をベースとした送達システムや、安定性を高めオフターゲット効果を最小化するための新規RNA修飾技術の探求などがあります。ゲノミクスとバイオテクノロジーの進歩が急速なペースであることから、市場情勢はダイナミックであり、高度な研究開発活動を伴う競争環境を特徴としています。進化する機会を活用するために、利害関係者は学際的なコラボレーションを重視し、AI主導の創薬を統合し、市場浸透を高めるためにスケーラブルな生産技術に投資すべきです。これらの要因に対処することは、RNA治療の進歩という有望な未来を活用することを目指す企業にとって極めて重要です。

市場力学：急速に進化するRNA療法市場の主要市場インサイトを公開

RNA療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 疾病病理におけるRNAの役割に対する理解の高まり
  • 個別化医療に対する需要の高まり
  • 製薬企業による戦略的提携による新規RNA療法開発の促進
• 市場抑制要因
  • RNA療法開発プロセスに関連する高コスト
• 市場機会
  • 政府および民間機関による研究開発活動への投資の増加
  • パイプライン化されたRNAベースの治療薬の臨床試験
• 市場の課題
  • RNA分子の不安定な性質と厳しい規制ガイドラインに起因する問題

ポーターの5つの力：RNA療法市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：RNA療法市場における外部からの影響の把握

外部マクロ環境要因は、RNA療法市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析RNA療法市場における競合情勢の把握

RNA療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスRNA療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、RNA療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 疾患病理におけるRNAの役割についての理解が深まる
    • 個別化医療の需要の高まり
    • 製薬企業による戦略的提携による新規医薬品開発の促進
  • 抑制要因
    • RNA療法開発プロセスに関連する高コスト
  • 機会
    • 政府および民間組織による研究開発活動への投資の増加
    • RNAベースの治療薬の臨床試験のパイプライン
  • 課題
    • RNA分子の不安定性から生じる問題と厳格な規制ガイドライン
• 市場セグメンテーション分析
  • テクノロジー：RNA療法の進歩を促進する技術に対する需要が高まっています。
  • 適応症：遺伝性疾患およびがん疾患におけるRNA療法の広範な応用。
  • エンドユーザー：診断と医薬品開発を推進する新たな発見に焦点を当てた学術調査の重要性が高まっています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 RNA療法市場：技術別

• 実現可能なテクノロジー
  • 阻害
  • ラベリング
  • 線形増幅
  • マイクロアレイ
  • 精製
  • 定量RT-PCR
• 実現技術
  • RNAアンチセンス技術
    • マイクロRNA
    • 低分子干渉RNA
  • RNA干渉技術

第7章 RNA療法市場適応症別

• がん
• 心臓血管
• 遺伝性疾患
• 感染症
• 腎臓疾患
• 代謝障害
• 腫瘍学
• 網膜疾患

第8章 RNA療法市場：エンドユーザー別

• 学術調査
• 診断
• 医薬品の発見と開発

第9章 南北アメリカのRNA療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のRNA療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのRNA療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 次世代RNA治療薬のリーダーであるADARx Pharmaceuticalsが、応募超過となった2億米ドルのシリーズC資金調達を発表
  • ReNAgade Therapeuticsが3億米ドルでRNA療法アリーナに参入
  • エスペロバックスとギンゴ・バイオワークスが環状RNAベースの治療薬開発で提携を発表

企業一覧

• Arbutus Biopharma Corporation
• NeuBase Therapeutics, Inc.
• Moderna, Inc.
• Arcturus Therapeutics Holdings Inc.
• BioNTech SE
• AstraZeneca PLC
• Arrowhead Pharmaceuticals, Inc.
• Nordic Nanovector ASA
• MiNA Therapeutics Limited
• Silence Therapeutics PLC
• Eli Lilly and Company
• Cartesian Therapeutics, Inc.
• Novartis AG
• Sirnaomics, Inc.
• F. Hoffmann-La Roche AG
• ProQR Therapeutics N.V.
• Cenix BioScience GmbH
• Nutcracker Therapeutics, Inc.
• Laronde
• Triplet Therapeutics, Inc.
• Ionis Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals, Inc.
• Deep Genomics
• Biogen Inc.
• GSK PLC
• Benitec Biopharma Limited
• Sanofi S.A.
• Novo Nordisk A/S

LIST OF FIGURES

• FIGURE 1. RNA THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. RNA THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RNA THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RNA THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INHIBITION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY LABELING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY LINEAR AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY QRT-PCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY MICRORNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY RNA INTERFERENCE TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY RETINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. CANADA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 56. CANADA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 57. CANADA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 58. CANADA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 59. CANADA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. CHINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 88. CHINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 89. CHINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 90. CHINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 91. CHINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. INDIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. INDIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 95. INDIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 96. INDIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 97. INDIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. INDONESIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. MALAYSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. PHILIPPINES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. SINGAPORE RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. TAIWAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. THAILAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. VIETNAM RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. DENMARK RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. EGYPT RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. FINLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 183. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. GERMANY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 195. ISRAEL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 196. ITALY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 197. ITALY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 198. ITALY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 199. ITALY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 200. ITALY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 201. ITALY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 207. NETHERLANDS RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 213. NIGERIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 219. NORWAY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 220. POLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 221. POLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 222. POLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 223. POLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 224. POLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 225. POLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 226. QATAR RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 227. QATAR RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 228. QATAR RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 229. QATAR RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 230. QATAR RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 231. QATAR RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 237. RUSSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 255. SPAIN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 261. SWEDEN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 267. SWITZERLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 273. TURKEY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 279. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 285. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 286. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 287. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The RNA Therapy Market was valued at USD 2.18 billion in 2023, expected to reach USD 2.60 billion in 2024, and is projected to grow at a CAGR of 22.38%, to USD 8.98 billion by 2030.

RNA therapy represents a cutting-edge segment of the biotechnology and pharmaceutical industries, focusing on the use of RNA molecules to treat a variety of diseases. This innovative approach includes RNA interference (RNAi), antisense oligonucleotides (ASOs), and messenger RNA (mRNA) therapies, which operate by targeting and manipulating genetic material. The necessity of RNA therapies is driven by their potential to treat conditions that are difficult to address with traditional small molecule and protein-based therapies, offering promise for genetic disorders, cancer, and rare diseases where precise genetic correction is crucial. The application and end-use scope of RNA therapy are expanding, with significant investments in drug discovery, clinical trials, and personalized medicine. Key growth factors include advancements in delivery technologies, increasing understanding of RNA mechanisms, and favorable regulatory frameworks. The latest potential opportunities in RNA therapy market innovation lie in refining delivery systems, expanding therapeutic targets, and developing cost-effective manufacturing processes. A focus on partnerships and collaborations with academic institutions and biotech companies could further accelerate innovation. However, challenges such as delivery efficacy, immunogenicity issues, and high development costs pose significant limitations, alongside regulatory hurdles and market competition. Areas ripe for innovation include nanoparticle-based delivery systems and the exploration of novel RNA modification techniques to enhance stability and minimize off-target effects. Given the rapid pace of advancements in genomics and biotechnology, the RNA therapy market is dynamic, characterized by a competitive landscape with a high degree of research and development activity. To capitalize on the evolving opportunities, stakeholders should emphasize interdisciplinary collaboration, integrate AI-driven drug discovery, and invest in scalable production technologies to enhance market penetration. Addressing these factors will be crucial for businesses aiming to capitalize on the promising future of RNA therapeutic advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving RNA Therapy Market

The RNA Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing understanding of the role of RNA in disease pathology
  • Heightened demand for personalized medicine
  • Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
• Market Restraints
  • High costs associated with RNA therapy development processes
• Market Opportunities
  • Increased investments by governments and private organizations in research and development activities
  • Pipelined clinical trials of RNA-based therapeutics
• Market Challenges
  • Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines

Porter's Five Forces: A Strategic Tool for Navigating the RNA Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the RNA Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the RNA Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the RNA Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the RNA Therapy Market

A detailed market share analysis in the RNA Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the RNA Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the RNA Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Arbutus Biopharma Corporation, NeuBase Therapeutics, Inc., Moderna, Inc., Arcturus Therapeutics Holdings Inc., BioNTech SE, AstraZeneca PLC, Arrowhead Pharmaceuticals, Inc., Nordic Nanovector ASA, MiNA Therapeutics Limited, Silence Therapeutics PLC, Eli Lilly and Company, Cartesian Therapeutics, Inc., Novartis AG, Sirnaomics, Inc., F. Hoffmann-La Roche AG, ProQR Therapeutics N.V., Cenix BioScience GmbH, Nutcracker Therapeutics, Inc., Laronde, Triplet Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Deep Genomics, Biogen Inc., GSK PLC, Benitec Biopharma Limited, Sanofi S.A., and Novo Nordisk A/S.

Market Segmentation & Coverage

This research report categorizes the RNA Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Enabled Technologies and Enabling Technologies. The Enabled Technologies is further studied across Inhibition, Labeling, Linear amplification, Microarrays, Purification, and qRT-PCR. The Enabling Technologies is further studied across RNA Antisense Technologies and RNA Interference Technologies. The RNA Antisense Technologies is further studied across MicroRNA and Small interfering RNA.
• Based on Indication, market is studied across Cancer, Cardiovascular, Genetic Disorders, Infectious Diseases, Kidney Diseases, Metabolic Disorders, Oncology, and Retinal Diseases.
• Based on End User, market is studied across Academic Research, Diagnostics, and Drug Discovery & Development.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing understanding of the role of RNA in disease pathology
    • 5.1.1.2. Heightened demand for personalized medicine
    • 5.1.1.3. Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with RNA therapy development processes
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased investments by governments and private organizations in research and development activities
    • 5.1.3.2. Pipelined clinical trials of RNA-based therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.
  • 5.2.2. Indication: Widespread applications of RNA therapy in genetic and cancer diseases.
  • 5.2.3. End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. RNA Therapy Market, by Technology

• 6.1. Introduction
• 6.2. Enabled Technologies
  • 6.2.1. Inhibition
  • 6.2.2. Labeling
  • 6.2.3. Linear amplification
  • 6.2.4. Microarrays
  • 6.2.5. Purification
  • 6.2.6. qRT-PCR
• 6.3. Enabling Technologies
  • 6.3.1. RNA Antisense Technologies
    • 6.3.1.1. MicroRNA
    • 6.3.1.2. Small interfering RNA
  • 6.3.2. RNA Interference Technologies

7. RNA Therapy Market, by Indication

• 7.1. Introduction
• 7.2. Cancer
• 7.3. Cardiovascular
• 7.4. Genetic Disorders
• 7.5. Infectious Diseases
• 7.6. Kidney Diseases
• 7.7. Metabolic Disorders
• 7.8. Oncology
• 7.9. Retinal Diseases

8. RNA Therapy Market, by End User

• 8.1. Introduction
• 8.2. Academic Research
• 8.3. Diagnostics
• 8.4. Drug Discovery & Development

9. Americas RNA Therapy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific RNA Therapy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa RNA Therapy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing
  • 12.3.2. ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million
  • 12.3.3. Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

Companies Mentioned

• 1. Arbutus Biopharma Corporation
• 2. NeuBase Therapeutics, Inc.
• 3. Moderna, Inc.
• 4. Arcturus Therapeutics Holdings Inc.
• 5. BioNTech SE
• 6. AstraZeneca PLC
• 7. Arrowhead Pharmaceuticals, Inc.
• 8. Nordic Nanovector ASA
• 9. MiNA Therapeutics Limited
• 10. Silence Therapeutics PLC
• 11. Eli Lilly and Company
• 12. Cartesian Therapeutics, Inc.
• 13. Novartis AG
• 14. Sirnaomics, Inc.
• 15. F. Hoffmann-La Roche AG
• 16. ProQR Therapeutics N.V.
• 17. Cenix BioScience GmbH
• 18. Nutcracker Therapeutics, Inc.
• 19. Laronde
• 20. Triplet Therapeutics, Inc.
• 21. Ionis Pharmaceuticals, Inc.
• 22. Alnylam Pharmaceuticals, Inc.
• 23. Deep Genomics
• 24. Biogen Inc.
• 25. GSK PLC
• 26. Benitec Biopharma Limited
• 27. Sanofi S.A.
• 28. Novo Nordisk A/S